Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients

Back to Hematopoietic Stem Cell Transplant (HSCT) trials

Recruiting

Plain-English translation of NCT07724873 on ClinicalTrials.gov ↗ · Source last updated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(2 sites)

India

Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, Maharashtra

Key details

Phase

Safety & dosing / Early efficacy

Sponsor

Tata Memorial Centre

Collaborators

Indian Council of Medical Research

Enrollment target

~54 participants

Started

January 2025

Primary completion

December 2029

Age range

18 Years and older

Last updated on clinicaltrials.gov in July 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Dr Akanksha Chichra, FNB, DNB Pediatric oncology

Tata Memorial Centre

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov